A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hyun Jun | - |
dc.contributor.author | Kim, Sae Woong | - |
dc.contributor.author | Kim, Je Jong | - |
dc.contributor.author | Lee, Sung Won | - |
dc.contributor.author | Paick, Jae Seung | - |
dc.contributor.author | Ahn, Tae Young | - |
dc.contributor.author | Park, Kwangsung | - |
dc.contributor.author | Park, Jong Kwan | - |
dc.contributor.author | Park, Nam Cheol | - |
dc.date.accessioned | 2021-09-03T05:45:03Z | - |
dc.date.available | 2021-09-03T05:45:03Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83352 | - |
dc.description.abstract | A multi-center, randomized, double-blind, placebo-controlled study was conducted with 158 subjects who were randomized to placebo or avanafil 50, 100, and 200 mg on demand for 8 weeks to evaluate the safety, tolerability, and efficacy of avanafil in the treatment of erectile dysfunction (ED) in Korean men. The primary outcome was the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire. Secondary outcomes included changes in the scores of IIEF questions 3 and 4 (IIEF Q3, Q4) from baseline, changes in all domain scores in the IIEF from baseline, Sexual Encounter Profile questions 2-5 (SEP2-5), the Global Efficacy Assessment Question (GEAQ), and the number of subjects whose EF domain score at the 8th week visit was >= 26. After 8 weeks of treatment, the dose groups except avanafil 50 mg scored significantly higher on the IIEF-EF domain from baseline than the placebo group. The changes from baseline in the avanafil group in IIEF Q3 (all doses) and Q4 (200 mg alone) were higher than the placebo group. The differences between avanafil and placebo groups were significant in SEP2 (100 and 200 mg) and SEP3-5 (200 mg). The differences in the GEAQ "Yes" response were also significant in the avanafil 100 and 200 mg groups. Regarding the ratio of normal EF at the end of the study, avanafil 200 mg differed significantly from the placebo. Most treatment-associated adverse events were mild and resolved spontaneously. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | INJECTION THERAPY | - |
dc.subject | INHIBITORS | - |
dc.subject | METAANALYSIS | - |
dc.subject | PREDICTORS | - |
dc.subject | SILDENAFIL | - |
dc.subject | DROPOUT | - |
dc.subject | INDEX | - |
dc.title | A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Je Jong | - |
dc.identifier.doi | 10.3346/jkms.2017.32.6.1016 | - |
dc.identifier.scopusid | 2-s2.0-85018439747 | - |
dc.identifier.wosid | 000403162400019 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.32, no.6, pp.1016 - 1023 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 32 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1016 | - |
dc.citation.endPage | 1023 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002227525 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | INJECTION THERAPY | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | SILDENAFIL | - |
dc.subject.keywordPlus | DROPOUT | - |
dc.subject.keywordPlus | INDEX | - |
dc.subject.keywordAuthor | Erectile Dysfunction | - |
dc.subject.keywordAuthor | Phosphodiesterase 5 Inhibitors | - |
dc.subject.keywordAuthor | Penile Erection | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.